GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Antibe Therapeutics Inc (TSX:ATE) » Definitions » E10

Antibe Therapeutics (TSX:ATE) E10 : C$-0.80 (As of Dec. 2023)


View and export this data going back to 2013. Start your Free Trial

What is Antibe Therapeutics E10?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Antibe Therapeutics's adjusted earnings per share data for the three months ended in Dec. 2023 was C$-0.080. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is C$-0.80 for the trailing ten years ended in Dec. 2023.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

As of today (2024-05-24), Antibe Therapeutics's current stock price is C$0.295. Antibe Therapeutics's E10 for the quarter that ended in Dec. 2023 was C$-0.80. Antibe Therapeutics's Shiller PE Ratio of today is .


Antibe Therapeutics E10 Historical Data

The historical data trend for Antibe Therapeutics's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Antibe Therapeutics E10 Chart

Antibe Therapeutics Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - -0.82 -0.84

Antibe Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.84 -0.84 -0.84 -0.83 -0.80

Competitive Comparison of Antibe Therapeutics's E10

For the Biotechnology subindustry, Antibe Therapeutics's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Antibe Therapeutics's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Antibe Therapeutics's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Antibe Therapeutics's Shiller PE Ratio falls into.



Antibe Therapeutics E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Antibe Therapeutics's adjusted earnings per share data for the three months ended in Dec. 2023 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=-0.08/125.0724*125.0724
=-0.080

Current CPI (Dec. 2023) = 125.0724.

Antibe Therapeutics Quarterly Data

per share eps CPI Adj_EPS
201403 -0.300 98.604 -0.381
201406 -0.400 99.473 -0.503
201409 -0.300 99.394 -0.378
201412 -0.200 98.367 -0.254
201503 -0.500 99.789 -0.627
201506 -0.100 100.500 -0.124
201509 -0.200 100.421 -0.249
201512 -0.100 99.947 -0.125
201603 -0.300 101.054 -0.371
201606 -0.100 102.002 -0.123
201609 -0.100 101.765 -0.123
201612 -0.200 101.449 -0.247
201703 -0.200 102.634 -0.244
201706 -0.200 103.029 -0.243
201709 -0.100 103.345 -0.121
201712 -0.100 103.345 -0.121
201803 -0.200 105.004 -0.238
201806 -0.100 105.557 -0.118
201809 -0.100 105.636 -0.118
201812 -0.200 105.399 -0.237
201903 -0.200 106.979 -0.234
201906 -0.100 107.690 -0.116
201909 -0.200 107.611 -0.232
201912 -0.150 107.769 -0.174
202003 -0.230 107.927 -0.267
202006 -0.160 108.401 -0.185
202009 -0.230 108.164 -0.266
202012 -0.170 108.559 -0.196
202103 -0.130 110.298 -0.147
202106 -0.130 111.720 -0.146
202109 -0.170 112.905 -0.188
202112 -0.090 113.774 -0.099
202203 -0.110 117.646 -0.117
202206 -0.100 120.806 -0.104
202209 -0.120 120.648 -0.124
202212 -0.080 120.964 -0.083
202303 -0.060 122.702 -0.061
202306 -0.110 124.203 -0.111
202309 -0.100 125.230 -0.100
202312 -0.080 125.072 -0.080

Add all the adjusted EPS together and divide 10 will get our e10.


Antibe Therapeutics  (TSX:ATE) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Antibe Therapeutics E10 Related Terms

Thank you for viewing the detailed overview of Antibe Therapeutics's E10 provided by GuruFocus.com. Please click on the following links to see related term pages.


Antibe Therapeutics (TSX:ATE) Business Description

Traded in Other Exchanges
Address
15 Prince Arthur Avenue, Toronto, ON, CAN, M5R 1B2
Antibe Therapeutics Inc is leveraging its proprietary hydrogen sulfide platform to develop next-generation safer therapies to target inflammation arising from a wide range of medical conditions. The company's pipeline includes assets that seek to overcome gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs. Antibe's lead drug, otenaproxesul, is in clinical development as a safer alternative to opioids for post-operative pain. Antibe's second pipeline drug, ATB-352, is being developed for a specialized acute pain indication. The company's anticipated next target is inflammatory bowel disease, a condition long in need of safer, more effective therapies.
Executives
Daniel Marcel Legault Senior Officer
Alain Wilson Senior Officer
John Lawrence Wallace Director, Director or Senior Officer of 10% Security Holder, Senior Officer
Nicolas Bourgeois Director or Senior Officer of Insider or Subsidiary (other than in 4,5,6)
Scott Wilson Curtis Senior Officer

Antibe Therapeutics (TSX:ATE) Headlines

No Headlines